Two mAbs take a stab at influenza's NActive site
Minh C Pham1, Kevin C O'Connor1
1Departments of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA. Email: minh.pham@yale.edu; kevin.oconnor@yale.edu.
Science Immunology
|November 7, 2020
Two human-derived recombinant mAbs specific for IBV bind the neuraminidase active site by emulating the enzymatic substrate, which results in broad protection.
Two human-derived recombinant mAbs specific for IBV bind the neuraminidase active site by emulating the enzymatic substrate, which results in broad protection.


